A trial conducted in Thailand evaluated the efficacy of different dosing strategies of a commercial Bacillus-based probiotic formulation (Sanolife® MIC, containing Bacillus subtilis, B. licheniformis, and B. pumilus) in Pacific whiteleg shrimp (Penaeus vannamei) larviculture from nauplius to post-larval stage 15 (PL15). Twelve 300-liter tanks stocked with 50,000 nauplii each were assigned to an untreated control (T1) or one of three probiotic concentrations: 1 g/m³/day (routine dose, T2), 5 g/m³/day (outbreak challenge dose, T3), and 30 g/m³/day (severe pressure dose, T4). Across all developmental stages, probiotic administration significantly suppressed Vibrio bacterial loads in both rearing water and shrimp larvae. By PL15, Vibrio counts were 2.1 to 4.6 times lower in probiotic treatments compared to the control. The 1 g/m³/day dose accelerated metamorphosis from mysis to PL1 (17% vs. 11% on day 9), while higher doses (30 g/m³/day) improved weight at PL6. Final survival at PL15 ranged from 85% to 87%, and post-salinity stress test survival was exceptionally high across all groups (98% to 99.5%). Tailoring probiotic application rates offers hatcheries an effective, antibiotic-free biocontrol method.